• Something wrong with this record ?

Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis

B. Sánchez Álamo, L. Moi, I. Bajema, M. Faurschou, O. Flossmann, T. Hauser, Z. Hruskova, D. Jayne, R. Luqmani, A. Mahr, A. Åkesson, K. Westman, EUVAS

. 2023 ; 38 (7) : 1655-1665. [pub] 2023Jun30

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23017041

Grant support
European Renal Association
Vasculitis Foundation
REGSKANE-824921 Region Skåne
Njurfonden

BACKGROUND: Despite newer treatments with immunosuppressive agents, there still exists a considerable morbidity and mortality risk among patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Since 1994 the European Vasculitis Society (EUVAS) has aimed for an improved outcome for patients with AAV, conducting several prospective randomized controlled trials (RCTs). The aim for the present study was to further evaluate the long-term survival of patients with AAV included in seven RCTs conducted by the EUVAS as well as to identify potential prognostic factors. METHODS: Long-term follow-up data were collected from questionnaires sent to the principal investigators of the original RCTs (1995-2012): MEPEX, NORAM, CYCAZAREM, CYCLOPS, IMPROVE, RITUXVAS and MYCYC, comprising 848 patients, all newly diagnosed with AAV. Relative survival estimates are presented for the study cohorts. Demographic, clinical and laboratory characteristics at trial entry were studied as potential prognostic factors in multivariable models. RESULTS: A total of 478 (56%) patients had granulomatosis with polyangiitis (GPA) and 370 (44%) had microscopic polyangiitis (MPA) with a mean age at diagnosis of 58 ± 14 years. The median follow-up time was 8 years (interquartile range 2.9-13.6). During the observation period there were 305 deaths and the main causes were infections (26%), cardiovascular disease (14%) and malignancies (13%). When compared with a matched cohort (regarding country, age group and sex) from the background population there were 14.2% more deaths among our cohort of AAV patients at 5 years, 19.9% at 10 years, 28.8% at 15 years and 36.3% at 20 years. The excess mortality occurred in all age groups. The estimated median survival time (from diagnosis) was 17.8 years (95% confidence interval 15.7-20). Among variables measured at baseline, advanced age, male sex, low estimated glomerular filtration rate and low platelet count were identified as predictors of death in a multivariate Cox model. CONCLUSIONS: Patients with AAV still have an increased risk of mortality compared with the general population despite newer therapeutic regimens. Treatment complications and organ damage are the main causes of limited survival and infections remain the leading cause of mortality among patients with AAV.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23017041
003      
CZ-PrNML
005      
20231026105339.0
007      
ta
008      
231013s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ndt/gfac320 $2 doi
035    __
$a (PubMed)36617233
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Sánchez Álamo, Beatriz $u Department of Clinical Sciences Lund, Division of Nephrology Lund University, Lund, Sweden
245    10
$a Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis / $c B. Sánchez Álamo, L. Moi, I. Bajema, M. Faurschou, O. Flossmann, T. Hauser, Z. Hruskova, D. Jayne, R. Luqmani, A. Mahr, A. Åkesson, K. Westman, EUVAS
520    9_
$a BACKGROUND: Despite newer treatments with immunosuppressive agents, there still exists a considerable morbidity and mortality risk among patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Since 1994 the European Vasculitis Society (EUVAS) has aimed for an improved outcome for patients with AAV, conducting several prospective randomized controlled trials (RCTs). The aim for the present study was to further evaluate the long-term survival of patients with AAV included in seven RCTs conducted by the EUVAS as well as to identify potential prognostic factors. METHODS: Long-term follow-up data were collected from questionnaires sent to the principal investigators of the original RCTs (1995-2012): MEPEX, NORAM, CYCAZAREM, CYCLOPS, IMPROVE, RITUXVAS and MYCYC, comprising 848 patients, all newly diagnosed with AAV. Relative survival estimates are presented for the study cohorts. Demographic, clinical and laboratory characteristics at trial entry were studied as potential prognostic factors in multivariable models. RESULTS: A total of 478 (56%) patients had granulomatosis with polyangiitis (GPA) and 370 (44%) had microscopic polyangiitis (MPA) with a mean age at diagnosis of 58 ± 14 years. The median follow-up time was 8 years (interquartile range 2.9-13.6). During the observation period there were 305 deaths and the main causes were infections (26%), cardiovascular disease (14%) and malignancies (13%). When compared with a matched cohort (regarding country, age group and sex) from the background population there were 14.2% more deaths among our cohort of AAV patients at 5 years, 19.9% at 10 years, 28.8% at 15 years and 36.3% at 20 years. The excess mortality occurred in all age groups. The estimated median survival time (from diagnosis) was 17.8 years (95% confidence interval 15.7-20). Among variables measured at baseline, advanced age, male sex, low estimated glomerular filtration rate and low platelet count were identified as predictors of death in a multivariate Cox model. CONCLUSIONS: Patients with AAV still have an increased risk of mortality compared with the general population despite newer therapeutic regimens. Treatment complications and organ damage are the main causes of limited survival and infections remain the leading cause of mortality among patients with AAV.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    _2
$a dospělí $7 D000328
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a předškolní dítě $7 D002675
650    12
$a granulomatóza s polyangiitidou $x diagnóza $x terapie $7 D014890
650    12
$a ANCA-asociované vaskulitidy $x terapie $x farmakoterapie $7 D056648
650    12
$a mikroskopická polyangiitida $x komplikace $x diagnóza $7 D055953
650    _2
$a protilátky proti cytoplazmě neutrofilů $7 D019268
650    _2
$a prognóza $7 D011379
655    _2
$a časopisecké články $7 D016428
700    1_
$a Moi, Laura $u Division of Immunology and Allergy, Department of Medicine, University Hospital of Lausanne, Lausanne University, Switzerland
700    1_
$a Bajema, Ingeborg $u Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
700    1_
$a Faurschou, Mikkel $u Department of Rheumatology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
700    1_
$a Flossmann, Oliver $u Department of Nephrology, Royal Berkshire Hospital, Reading, Berkshire, UK
700    1_
$a Hauser, Thomas $u IZZ Immunologie-Zentrum Zürich, Zürich, Switzerland
700    1_
$a Hruskova, Zdenka $u Department of Nephrology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Jayne, David $u Department of Medicine, University of Cambridge, Cambridge, UK
700    1_
$a Luqmani, Raashid $u Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
700    1_
$a Mahr, Alfred $u Clinic for Rheumatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
700    1_
$a Åkesson, Anna $u Clinical Studies Sweden Forum South, Skåne University Hospital Lund, Lund, Sweden
700    1_
$a Westman, Kerstin $u Department of Clinical Sciences Lund, Division of Nephrology Lund University, Lund, Sweden $u Department of Nephrology, Skåne University Hospital Malmö-Lund, Lund, Malmö, Sweden
710    2_
$a EUVAS
773    0_
$w MED00010288 $t Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association $x 1460-2385 $g Roč. 38, č. 7 (2023), s. 1655-1665
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36617233 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105333 $b ABA008
999    __
$a ok $b bmc $g 2000523 $s 1203403
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 38 $c 7 $d 1655-1665 $e 2023Jun30 $i 1460-2385 $m Nephrology, dialysis, transplantation $n Nephrol Dial Transplant $x MED00010288
GRA    __
$p European Renal Association
GRA    __
$p Vasculitis Foundation
GRA    __
$a REGSKANE-824921 $p Region Skåne
GRA    __
$p Njurfonden
LZP    __
$a Pubmed-20231013

Find record

Citation metrics

Archiving options